8-K: Medicus Pharma CFO Takes Medical Leave; Acting CFO Appointed

Medicus Pharma Ltd. announced that its Chief Financial Officer, James Quinlan, is taking a medical leave of absence, with President Carolyn Bonner stepping in as Acting CFO.

Summary

• James Quinlan, Chief Financial Officer of Medicus Pharma Ltd., commenced a medical leave of absence on September 12, 2025.
• Carolyn Bonner, who has served as the Company's President since September 2023, has been appointed as Acting Chief Financial Officer.
• Ms. Bonner will continue in her role as President and will not receive any additional compensation for her service as Acting CFO.
• Ms. Bonner brings extensive experience, including prior roles as President & CEO of Parkway Clinical Laboratories (2019-2023) and Director of Corporate Development at Building Beyond BRIC Investment Fund (2019-2023 and 2009-2011).

Sentiment

Score: 5

Explanation: The unexpected medical leave of the CFO introduces some uncertainty, but the immediate appointment of the experienced President, Carolyn Bonner, as Acting CFO, without additional compensation, provides continuity and stability, leading to a neutral sentiment.

Positives

• The immediate appointment of an experienced internal candidate, Carolyn Bonner, as Acting CFO ensures continuity in financial leadership.
• Ms. Bonner's background as President & CEO of a diagnostic company and in corporate development roles provides relevant expertise for the Acting CFO position.
• No additional compensation will be provided to Ms. Bonner for her service as Acting CFO, potentially avoiding increased overhead costs.

Negatives

• The Chief Financial Officer, James Quinlan, is taking an unexpected medical leave of absence, which can introduce uncertainty.
• A change in a key executive role, even temporary, may lead to a period of adjustment for the company's operations.

Risks

• Potential for operational disruption or delays in financial initiatives due to the unexpected medical leave of the Chief Financial Officer.
• Increased workload and potential strain on resources for Carolyn Bonner, who will concurrently serve as both President and Acting CFO.

Management Changes

Stakeholder Impact

• Shareholders: May experience short-term uncertainty due to the change in a key executive role, though mitigated by the appointment of an internal, experienced Acting CFO.
• Employees: May experience organizational adjustments as leadership roles shift, particularly for those reporting to the CFO or President.
• Management: Carolyn Bonner will assume increased responsibilities by holding both President and Acting CFO roles concurrently.

Key Dates

Keywords

Medicus Pharma, CFO, Chief Financial Officer, medical leave, Carolyn Bonner, executive change, corporate governance, NASDAQ, MDCX, pharmaceutical, biotech